KNOXVILLE, Tenn.—The U.S. Patent and Trademark Office has allowed Provectus’ patent application for the use of adoptive cell transfer of PV-10-induced T cells for treating solid tumor cancers, the company announced recently. Under the patent’s treatment concept, PV-10 is injected into solid tumors, and then T cells trained through PV-10 oncolytic immunotherapy to target treated tumors are harvested, banked and amplified. These amplified T cells can then be administered via adoptive cell transfer. The patent covers such treatment for either the original patient or other immunologically suitable patients. PV-10, an investigational drug for treating adult/pediatric solid tumor cancers, is the first small-molecule oncolytic immunotherapy. PV-10 is administered through intralesional injection into superficial or visceral tumors to trigger immunogenic cell death, and is being evaluated in multiple cancer types.